oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2026-25-2-145-154oncotomsk-4207Research ArticleОБЗОРЫREVIEWSИнфекция H. pylori при опухолях ЖКТ: влияние на развитие, прогноз и эффективность противоопухолевой терапии. Обзор литературыH. pylori infection in gastrointestinal cancer: impact on the development, prognosis, and effectiveness of anticancer therapy. Literature reviewhttps://orcid.org/0000-0002-3523-1744МакароваМ. И.MakarovaM. I.

Макарова Мария Ивановна - онколог 3-го онкологического отделения.

603093, Нижний Новгород, ул. Родионова, 190

Maria I. Makarova - MD, Oncologist, Oncology Department, Research Institute of Clinical Oncology.

190, Rodionova St., Nizhny Novgorod, 603093

https://orcid.org/0000-0003-4295-1843ШумскаяИ. С.ShumskayaI. S.

Шумская Ирина Сергеевна - кандидат медицинских наук, начальник химиотерапевтической службы стационара № 1, ГАУЗ НО «НИИ клинической онкологии «Нижегородский областной клинический онкологический диспансер»; ассистент кафедры онкологии, лучевой терапии и радиологии им. проф. Н.Е. Яхонтова, ФГБОУ ВО «Приволжский ИМУ» Минздрава России.

603093, Нижний Новгород, ул. Родионова, 190; 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1

Irina S. Shumskaya - MD, PhD, Head of the Chemotherapy Department, Hospital No. 1, Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncology Center; Assistant, Department of Oncology, Radiation Therapy and Radiology named after Professor N.E. Yakhontov, Privolzhsky RMU, Ministry of Health of Russia.

190, Rodionova St., Nizhny Novgorod, 603093; 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603005

medicanns@mail.ruhttps://orcid.org/0000-0002-0859-4339КолесниковаЕ. А.KolesnikovaE. A.

Колесникова Елена Александровна - кандидат биологических наук, заведующая молекулярно-генетической лабораторией ОПАО.

603093, Нижний Новгород, ул. Родионова, 190

Elena A. Kolesnikova - PhD, Head of the Molecular Genetic Laboratory, Research Institute of Clinical Oncology.

190, Rodionova St., Nizhny Novgorod, 603093

https://orcid.org/0000-0002-9202-1321КиселевН. М.KiselyovN. M.

Киселев Николай Михайлович - кандидат медицинских наук, заведующий 2-м онкологическим отделением абдоминальной онкологии и рентгенхирургических методов диагностики и лечения, ГАУЗ НО «НИИ клинической онкологии «Нижегородский областной клинический онкологический диспансер»; доцент кафедры факультетской хирургии и трансплантологии, ФГБОУ ВО «Приволжский ИМУ» Минздрава России.

603093, Нижний Новгород, ул. Родионова, 190; 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1

Nikolay M. Kiselyov - MD, PhD, Head of Department of Abdominal Oncology and X-ray Surgical Methods of Diagnosis and Treatment, Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncology Center; Associate Professor, Department of Faculty Surgery and Transplantology, Privolzhsky RMU, Ministry of Health of Russia.

190, Rodionova St., Nizhny Novgorod, 603093; 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603005

https://orcid.org/0000-0003-3302-1687РадовскийВ. В.RadovskyV. V.

Радовский Вячеслав Валерьевич - патологоанатом, начальник объединенного патологоанатомического отделения.

603093, Нижний Новгород, ул. Родионова, 190

Vyacheslav V. Radovsky - MD, Pathologist, Head of Pathological Anatomy Department, Research Institute of Clinical Oncology.

190, Rodionova St., Nizhny Novgorod, 603093

https://orcid.org/0000-0002-0223-0753ГамаюновС. В.GamayunovS. V.

Гамаюнов Сергей Викторович - доктор медицинских наук, главный врач, ГАУЗ НО «НИИ клинической онкологии «Нижегородский областной клинический онкологический диспансер»; профессор кафедры онкологии, лучевой терапии и радиологии им. проф. Н.Е. Яхонтова, ФГБОУ ВО «Приволжский ИМУ» Минздрава России.

603093, Нижний Новгород, ул. Родионова, 190; 603005, Нижний Новгород, пл. Минина и Пожарского, 10/1

Sergey V. Gamayunov - MD, DSc, Chief Physician, Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncology Center; Professor, Department of Oncology, Radiation Therapy and Radiology named after Professor N.E. Yakhontov, Privolzhsky RMU, Ministry of Health of Russia.

190, Rodionova St., Nizhny Novgorod, 603093; 10/1, Minin and Pozharsky Sq., Nizhny Novgorod, 603005

ГАУЗ НО «Научно-исследовательский институт клинической онкологии «Нижегородский областной клинический онкологический диспансер»РоссияResearch institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncology CenterRussian FederationГАУЗ НО «Научно-исследовательский институт клинической онкологии «Нижегородский областной клинический онкологический диспансер»; ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияResearch institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncology Center; Privolzhsky Research Medical University, Ministry of Health of RussiaRussian Federation202617052026252145154Copyright © Макарова М.И., Шумская И.С., Колесникова Е.А., Киселев Н.М., Радовский В.В., Гамаюнов С.В., 20262026Макарова М.И., Шумская И.С., Колесникова Е.А., Киселев Н.М., Радовский В.В., Гамаюнов С.В.Makarova M.I., Shumskaya I.S., Kolesnikova E.A., Kiselyov N.M., Radovsky V.V., Gamayunov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/4207

Цель исследования – представить обзор современных научных данных о влиянии H. pylori и эрадикационной терапии данной инфекции на развитие, течение и результаты лечения опухолей желудочнокишечного тракта. Материал и методы. Проведен поиск зарубежных и отечественных литературных источников, опубликованных в базах данных MedLine, Pubmed, Scopus, The Cochrane Library, РИНЦ в период с 2004 по 2025 г. Проанализированы 53 доступные научные публикации, в том числе 5 российских и 48 зарубежных, из них: 41 статья, 10 метаанализов, 2 ретроспективных исследования.

Результаты

Результаты. Анализ научных работ показал, что инфекция H. pylori может существенно ухудшать результаты лечения больных с уже диагностированным раком желудка. Литературные данные демонстрируют положительное влияние эрадикации H. pylori на выживаемость как при раннем, так и при распространенном раке желудка. Помимо того, что инфекция H. pylori является основным фактором риска развития рака желудка, она также связана с повышенным риском развития колоректального рака, аденокарциномы пищевода, рака поджелудочной железы, рака желчевыводящих путей. H. pylori влияет на эффективность иммунотерапии при лечении злокачественных новообразований.

Заключение

Заключение. Инфекция H. pylori и эрадикационная терапия могут оказывать влияние на развитие и течение опухолей желудочно-кишечного тракта. Несмотря на пристальное внимание к данной проблеме, ключевые вопросы остаются не до конца изученными.

Study Objective

Study Objective: to provide an overview of current scientific data on the impact of H. pylori infection and eradication therapy on the development, clinical course and treatment outcomes of gastrointestinal cancer.

Material and Methods

Material and Methods. A search of Russian and English-language literature sources published in various databases (MedLine, Pubmed, Scopus, The Cochrane Library, and Russian Science Citation Index) between 2004 and 2025 was conducted. Fifty-three available scientific publications were analyzed, including 5 Russian and 48 foreign publications, including 41 articles, 10 meta-analyses, and 2 retrospective studies.

Results

Results. An analysis of scientific papers showed that H. pylori infection significantly worsened treatment outcomes and survival in patients with already diagnosed gastric cancer. Literature data demonstrate a positive impact of H. pylori eradication on survival in both early and advanced gastric cancer. In addition to being a major risk factor for stomach cancer, H. pylori infection is also associated with an increased risk of colorectal cancer, esophageal adenocarcinoma, pancreatic cancer, and biliary tract cancer. Furthermore, H. pylori infection impacts the effectiveness of immunotherapy in cancer treatment

Conclusion

Conclusion. H. pylori infection and eradication therapy can influence the development and clinical course of gastrointestinal tumors. Despite the close attention of many scientists to this issue, key questions remain poorly understood.

Helicobacter pyloriрак желудкарак толстой кишкирак поджелудочной железырак билиарной системыиммунотерапияхимиотерапияэрадикацияHelicobacter pyloristomach cancercolon cancerpancreatic cancerbiliary tract cancerЭто исследование не потребовало дополнительного финансированияThis study required no fundingReferencesReshetnyak V.I., Burmistrov A.I., Maev I.V. Helicobacter pylori: Commensal, symbiont or pathogen? World J. Gastroenterol. 2021; 27(7): 545–60. doi: 10.3748/wjg.v27.i7.545Reshetnyak V.I., Burmistrov A.I., Maev I.V. Helicobacter pylori: Commensal, symbiont or pathogen? World J. Gastroenterol. 2021; 27(7): 545–60. doi: 10.3748/wjg.v27.i7.545Ивашкин В.Т., Лапина Т.Л., Маев И.В., Драпкина О.М., Козлов Р.С., Шептулин А.А., Трухманов А.С., Абдулхаков С.Р., Алексеева О.П., Алексеенко С.А., Андреев Д.Н., Бордин Д.С., Дехнич Н.Н., Кляритская И.Л., Корочанская Н.В., Осипенко М.Ф., Полуэктова Е.А., Сарсенбаева А.С., Симаненков В.И., Ткачев А.В., Ульянин А.И., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(6): 72–93. doi: 10.22416/1382-4376-2022-32-6-72-93. EDN: QRQFTQ.Ivashkin V.T., Lapina T.L., Maev I.V., Drapkina O.M., Kozlov R.S., Sheptulin A.A., Trukhmanov A.S., Abdulkhakov S.R., Alekseeva O.P., Alekseenko S.A., Andreev D.N., Bordin D.S., Dekhnich N.N., Klyaritskaya I.L., Korochanskaya N.V., Osipenko M.F., Poluektova E.A., Sarsenbaeva A.S., Simanenkov V.I., Tkachev A.V., Ulyanin A.I., Khlynov I.B., Tsukanov V.V. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32(6): 72–93. (in Russian). doi: 10.22416/1382-4376-2022-32-6-72-93. EDN: QRQFTQ.Marshall B.J., Warren L.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390): 1311–15. doi: 10.1016/s0140-6736(84)91816-6.Marshall B.J., Warren L.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390): 1311–15. doi: 10.1016/s0140-6736(84)91816-6.Бордин Д.С., Шенгелия М.И., Иванова В.А., Войнова И.Н. История открытия бактерии Helicobacter pylori. Терапевтический архив. 2022; 94(2): 283–88. doi: 10.26442/00403660.2022.02.201377. EDN: NXTBRY.Bordin D.S., Shengelia M.I., Ivanova V.A., Voynova I.N. The history of the discovery of the Helicobacter pylori. Therapeutic Archive. 2022; 94(2): 283–88. (in Russian). doi: 10.26442/00403660.2022.02.201377. EDN: NXTBRY.de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8(2): e180–e190. doi: 10.1016/S2214109X(19)30488-7.de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8(2): e180–e190. doi: 10.1016/S2214109X(19)30488-7.Salvatori S., Marafini I., Laudisi F., Monteleone G., Stolfi C. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int. J. Mol. Sci. 2023; 24(3): 2895. doi: 10.3390/ijms24032895.Salvatori S., Marafini I., Laudisi F., Monteleone G., Stolfi C. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int. J. Mol. Sci. 2023; 24(3): 2895. doi: 10.3390/ijms24032895.Hoft S.G., Noto C.N., DiPaolo R.J. Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity. Front Cell Dev Biol. 2021; 9: 752346. doi: 10.3389/fcell.2021.752346.Hoft S.G., Noto C.N., DiPaolo R.J. Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity. Front Cell Dev Biol. 2021; 9: 752346. doi: 10.3389/fcell.2021.752346.Palrasu M., Zaika E., El-Rifai W., Que J., Zaika A.I. Role of Bacterial and Viral Pathogens in Gastric Carcinogenesis. Cancers (Basel). 2021; 13(8): 1878. doi: 10.3390/cancers13081878.Palrasu M., Zaika E., El-Rifai W., Que J., Zaika A.I. Role of Bacterial and Viral Pathogens in Gastric Carcinogenesis. Cancers (Basel). 2021; 13(8): 1878. doi: 10.3390/cancers13081878.Исаева Г.Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori. Клиническая микробиология и антимикробная химиотерапия. 2018; 20(1): 14–23. EDN: UOGXEB.Исаева Г.Ш., Валиева Р.И. Биологические свойства и вирулентность Helicobacter pylori. Клиническая микробиология и антимикробная химиотерапия. 2018; 20(1): 14–23. [Isaeva G.Sh., Valieva R.I. Biological characteristics and virulence of Helicobacter pylori. Clinical microbiology and antimicrobial chemotherapy. 2018; 20(1): 14–23. (in Russian). EDN: UOGXEB.Hatakeyama M. Malignant Helicobacter pylori-associated diseases: Gastric cancer and MALT lymphoma. Adv. Exp. Med. Biol. 2019; 1149: 135–49. doi: 10.1007/5584_2019_363.Hatakeyama M. Malignant Helicobacter pylori-associated diseases: Gastric cancer and MALT lymphoma. Adv. Exp. Med. Biol. 2019; 1149: 135–49. doi: 10.1007/5584_2019_363.Hansen L.M., Dekalb D.J., Cai L.P., Solnick J.V. Identification of Pathogenicity Island Genes Associated with Loss of Type IV Secretion Function during Murine Infection with Helicobacter pylori. Infect Immun. 2020; 88(6): e00801–19. doi: 10.1128/IAI.00801-19.Hansen L.M., Dekalb D.J., Cai L.P., Solnick J.V. Identification of Pathogenicity Island Genes Associated with Loss of Type IV Secretion Function during Murine Infection with Helicobacter pylori. Infect Immun. 2020; 88(6): e00801–19. doi: 10.1128/IAI.00801-19.Yamaoka Y., Saruuljavkhlan B., Alfaray R.I., Linz B. Pathogenomics of Helicobacter pylori. Curr Top Microbiol Immunol. 2023; 444: 117–55. doi: 10.1007/978-3-031-47331-9_5.Yamaoka Y., Saruuljavkhlan B., Alfaray R.I., Linz B. Pathogenomics of Helicobacter pylori. Curr Top Microbiol Immunol. 2023; 444: 117–55. doi: 10.1007/978-3-031-47331-9_5.Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019; 11(11): 677. doi: 10.3390/toxins11110677.Ansari S., Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019; 11(11): 677. doi: 10.3390/toxins11110677.Toyoshima O., Nishizawa T., Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J. Gastroenterol. 2020; 26(5): 466–77. doi: 10.3748/wjg.v26.i5.466.Toyoshima O., Nishizawa T., Koike K. Endoscopic Kyoto classification of Helicobacter pylori infection and gastric cancer risk diagnosis. World J. Gastroenterol. 2020; 26(5): 466–77. doi: 10.3748/wjg.v26.i5.466.Ивашкин В.Т., Маев И.В., Каприн А.Д., Агапов М.Ю., Андреев Д.Н., Водолеев А.С., Жаркова М.Ю., Королев М.П., Кучерявый Ю.А., Лапина Т.Л., Маевская М.В., Охлобыстин А.В., Павлов Ч.С., Параскевова А.В., Пирогов С.С., Полуэктова Е.А., Румянцева Д.Е., Трухманов А.С., Царьков П.В., Шептулин А.А., Шифрин О.С. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019; 29(5): 53–74. doi: 10.22416/1382-4376-2019-29-5-53-74. EDN: XYHWQO.Ivashkin V.T., Mayev I.V., Kaprin A.D., Agapov M.Yu., Andreev D.N., Vodoleev A.S., Zharkova M.Yu., Korolev M.P., Kucheryavyi Yu.A., Lapina T.L., Mayevskaya M.V., Okhlobystin A.V., Pavlov Ch.S., Paraskevova A.V., Pirogov S.S., Poluektova E.A., Rumyantseva D.E., Trukhmanov A.S., Tsarkov P.V., Sheptulin A.A., Shifrin O.S. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29(5): 53–74. (in Russian). doi: 10.22416/1382-4376-2019-29-5-53-74. EDN: XYHWQO.Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., Terao S., Amagai K., Hayashi S., Asaka M.. Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372(9636): 392–97. doi: 10.1016/S0140-6736(08)61159-9.Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., Terao S., Amagai K., Hayashi S., Asaka M.. Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372(9636): 392–97. doi: 10.1016/S0140-6736(08)61159-9.Choi I.J., Kook M.C., Kim Y.I., Cho S.J., Lee J.Y., Kim C.G., Park B., Nam B.H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018; 378(12): 1085–95. doi: 10.1056/NEJMoa1708423.Choi I.J., Kook M.C., Kim Y.I., Cho S.J., Lee J.Y., Kim C.G., Park B., Nam B.H. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018; 378(12): 1085–95. doi: 10.1056/NEJMoa1708423.Zhao Z., Zhang R., Chen G., Nie M., Zhang F., Chen X., Lin J., Chen Z., Lin F., Wei C., Zheng Z., Ruan S., Huang B., Chen Y., Nie R. Anti-Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy. JAMA Netw Open. 2024; 7(3): e243812. doi: 10.1001/jamanetworkopen.2024.3812.Zhao Z., Zhang R., Chen G., Nie M., Zhang F., Chen X., Lin J., Chen Z., Lin F., Wei C., Zheng Z., Ruan S., Huang B., Chen Y., Nie R. Anti-Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy. JAMA Netw Open. 2024; 7(3): e243812. doi: 10.1001/jamanetworkopen.2024.3812.Киселев Н.М., Климин С.А., Колесник Я.И., Кокорин Р.С., Ашимов Э.А., Елагина В.Ю., Шумская И.С., Загайнов В.Е., Гамаюнов С.В. Периоперационная химиотерапия и морфологический ответ в лечении рака желудка. Современная онкология. 2024; 26(3): 276–83. doi: 10.26442/18151434.2024.3.202978. EDN: LWZBVP.Kiselev N.M., Klimin S.A., Kolesnik Ya.I., Kokorin R.S., Ashimov E.A., Elagina V.Yu., Shumskaya I.S., Zagainov V.E., Gamayunov S.V. Perioperative chemotherapy and morphological response in the treatment of gastric cancer. Modern Oncology. 2024; 26(3): 276–83. (in Russian).]. doi: 10.26442/18151434.2024.3.202978. EDN: LWZBVP.Zhong B., Xiong Z., Zheng J., Mohamed S.A, Sun J., Huang D., Deng Z., Guo J., Peng J., Wang H., Lian L. Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis. BMC Cancer. 2025; 25(1): 157. doi: 10.1186/s12885-025-13494-5.Zhong B., Xiong Z., Zheng J., Mohamed S.A, Sun J., Huang D., Deng Z., Guo J., Peng J., Wang H., Lian L. Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis. BMC Cancer. 2025; 25(1): 157. doi: 10.1186/s12885-025-13494-5.Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.Jia Z., Zheng M., Jiang J., Cao D., Wu Y., Zhang Y., Fu Y., Cao X. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. BMC Cancer. 2022; 22(1): 155. doi: 10.1186/s12885-022-09222-y.Jia Z., Zheng M., Jiang J., Cao D., Wu Y., Zhang Y., Fu Y., Cao X. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. BMC Cancer. 2022; 22(1): 155. doi: 10.1186/s12885-022-09222-y.Engelsberger V., Gerhard M., Mejías-Luque R. Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. Front Cell Infect Microbiol. 2024; 14: 1339750. doi: 10.3389/ fcimb.2024.1339750Engelsberger V., Gerhard M., Mejías-Luque R. Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. Front Cell Infect Microbiol. 2024; 14: 1339750. doi: 10.3389/fcimb.2024.1339750Hu K.C., Wu M.S., Chu C.H., Wang H.Y., Lin S.C., Liu C.C., Su T.H., Liao W.C., Chen C.L., Liu C.J., Shih S.C. Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. Clin Infect Dis. 2019; 68(12): 2105–13. doi: 10.1093/cid/ciy591.Hu K.C., Wu M.S., Chu C.H., Wang H.Y., Lin S.C., Liu C.C., Su T.H., Liao W.C., Chen C.L., Liu C.J., Shih S.C. Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. Clin Infect Dis. 2019; 68(12): 2105–13. doi: 10.1093/cid/ ciy591.Guo C.G., Zhang F., Jiang F., Wang L., Chen Y., Zhang W., Zhou A., Zhang S., Leung W.K. Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences. Therap Adv Gastroenterol. 2023; 16: 17562848231170943. doi: 10.1177/17562848231170943.Guo C.G., Zhang F., Jiang F., Wang L., Chen Y., Zhang W., Zhou A., Zhang S., Leung W.K. Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences. Therap Adv Gastroenterol. 2023; 16: 17562848231170943. doi: 10.1177/17562848231170943.Gao H., Li L., Zhang C., Tu J., Geng X., Wang J., Zhou X., Jing J., Pan W. Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer. Gastroenterol Res Pract. 2019; 2019: 1953497. doi: 10.1155/2019/1953497.Gao H., Li L., Zhang C., Tu J., Geng X., Wang J., Zhou X., Jing J., Pan W. Systematic Review with Meta-analysis: Association of Helicobacter pylori Infection with Esophageal Cancer. Gastroenterol Res Pract. 2019; 2019: 1953497. doi: 10.1155/2019/1953497.Nie S., Chen T., Yang X., Huai P., Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014; 27(7): 645–53. doi: 10.1111/dote.12194.Nie S., Chen T., Yang X., Huai P., Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014; 27(7): 645–53. doi: 10.1111/dote.12194.Xie F.J., Zhang Y.P., Zheng Q.Q., Jin H.C., Wang F.L., Chen M., Shao L., Zou D.H., Yu X.M., Mao W.M. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013; 19(36): 6098–107. doi: 10.3748/wjg.v19.i36.6098.Xie F.J., Zhang Y.P., Zheng Q.Q., Jin H.C., Wang F.L., Chen M., Shao L., Zou D.H., Yu X.M., Mao W.M. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013; 19(36): 6098–107. doi: 10.3748/wjg.v19.i36.6098.Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008; 1(5): 329–38. doi: 10.1158/1940-6207.CAPR-08-0109.Islami F., Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008; 1(5): 329–38. doi: 10.1158/1940-6207.CAPR-08-0109.Zhuo X., Zhang Y., Wang Y., Zhuo W., Zhu Y., Zhang X.. Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses. Clin Oncol (R Coll Radiol). 2008; 20(10): 757–62. doi: 10.1016/j.clon.2008.07.005.Zhuo X., Zhang Y., Wang Y., Zhuo W., Zhu Y., Zhang X.. Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses. Clin Oncol (R Coll Radiol). 2008; 20(10): 757–62. doi: 10.1016/j.clon.2008.07.005.Rokkas T., Pistiolas D., Sechopoulos P., Robotis I., Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007; 5(12): 1413–7, 1417.e1–2. doi: 10.1016/j.cgh.2007.08.010.Rokkas T., Pistiolas D., Sechopoulos P., Robotis I., Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007; 5(12): 1413–7, 1417.e1–2. doi: 10.1016/j.cgh.2007.08.010.Xie T., Cui X., Zheng H., Chen D., He L., Jiang B. Metaanalysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013; 25(10): 1195–205. doi: 10.1097/MEG.0b013e328363e2c7.Xie T., Cui X., Zheng H., Chen D., He L., Jiang B. Metaanalysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013; 25(10): 1195–205. doi: 10.1097/MEG.0b013e328363e2c7.Kotta A.S., Kelling A.S., Corleto K.A., Sun Y., Giles E.D. Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression. Biomolecules. 2022; 2(4): 483. doi: 10.3390/biom12040483.Kotta A.S., Kelling A.S., Corleto K.A., Sun Y., Giles E.D. Ghrelin and Cancer: Examining the Roles of the Ghrelin Axis in Tumor Growth and Progression. Biomolecules. 2022; 2(4): 483. doi: 10.3390/biom12040483.Bhatt A., Zaidi H.M., Maitra R., Goel S. Infectious Agents and Esophageal Cancer: A Comprehensive Review. Cancers (Basel). 2025; 17(7): 1248. doi: 10.3390/cancers17071248.Bhatt A., Zaidi H.M., Maitra R., Goel S. Infectious Agents and Esophageal Cancer: A Comprehensive Review. Cancers (Basel). 2025; 17(7): 1248. doi: 10.3390/cancers17071248.Hu H.M., Kuo C.H., Lee C.H., Wu I.C., Lee K.W., Lee J.M., Goan Y.G., Chou S.H., Kao E.L., Wu M.T., Wu D.C. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol. 2009; 9: 37. doi: 10.1186/1471230X-9-37.Hu H.M., Kuo C.H., Lee C.H., Wu I.C., Lee K.W., Lee J.M., Goan Y.G., Chou S.H., Kao E.L., Wu M.T., Wu D.C. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol. 2009; 9: 37. doi: 10.1186/1471230X-9-37.Maity R., Dhali A., Biswas J. Is Helicobacter pylori infection protective against esophageal cancer? World J Gastroenterol. 2024; 30(38): 4168–4174. doi: 10.3748/wjg.v30.i38.4168.Maity R., Dhali A., Biswas J. Is Helicobacter pylori infection protective against esophageal cancer? World J Gastroenterol. 2024; 30(38): 4168–4174. doi: 10.3748/wjg.v30.i38.4168.Wiklund A.K., Santoni G. Yan J., Radkiewicz C., Xie S., Birgisson H., Ness-Jensen E., von Euler-Chelpin M., Kauppila J.H., Lagergren J. Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study. Gastroenterology. 2024; 167(3): 485–92.e3. doi: 10.1053/j.gastro.2024.03.016.Wiklund A.K., Santoni G. Yan J., Radkiewicz C., Xie S., Birgisson H., Ness-Jensen E., von Euler-Chelpin M., Kauppila J.H., Lagergren J. Risk of Esophageal Adenocarcinoma After Helicobacter pylori Eradication Treatment in a Population-Based Multinational Cohort Study. Gastroenterology. 2024; 167(3): 485–92.e3. doi: 10.1053/j.gastro.2024.03.016.Колесникова Е.А., Бодунова Н.А., Данишевич А.М., Никифорова Е.С., Шаталов П.А., Шумская И.С., Малинина П.А., Гамаюнов С.В., Кучин Д.М., Киселев Н.М., Загайнов В.Е. Спектр мутаций в генах наследственных опухолевых синдромов при раке поджелудочной железы. Поволжский онкологический вестник. 2023; 14(4): 49–56. doi: 10.32000/2078-1466-2023-4-49-56. EDN: BGEEAW.Kolesnikova E.A., Bodunova N.A., Danishevich A.M., Nikiforova E.S., Shatalov P.A., Shumskaya I.S., Malinina P.A., Gamayunov S.V., Kuchin D.M., Kiselyov N.M., Zagainov V.E. Spectrum mutations in the genes of hereditary tumor syndromes in pancreatic cancer. Oncology Bulletin of the Volga Region. 2023; 14(4): 49–56. (in Russian). doi: 10.32000/2078-1466-2023-4-49-56. EDN: BGEEAW.Xu W., Zhou X., Yin M., Gao J., Weng Z., Xu C. The relationship between Helicobacter pylori and pancreatic cancer: a meta-analysis. Transl Cancer Res. 2022; 11(8): 2810–22. doi: 10.21037/tcr-21-2803.Xu W., Zhou X., Yin M., Gao J., Weng Z., Xu C. The relationship between Helicobacter pylori and pancreatic cancer: a meta-analysis. Transl Cancer Res. 2022; 11(8): 2810–22. doi: 10.21037/tcr-21-2803.Yadav D., Lowenfels A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6): 1252–61. doi: 10.1053/j.gastro.2013.01.068.Yadav D., Lowenfels A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6): 1252–61. doi: 10.1053/j.gastro.2013.01.068.Yu J., Yang P., Qin X., Li C., Lv Y., Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022; 27(1): e12860. doi: 10.1111/hel.12860.Yu J., Yang P., Qin X., Li C., Lv Y., Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022; 27(1): e12860. doi: 10.1111/hel.12860.Wang Y., Zhang F.C., Wang Y.J. Helicobacter pylori and pancreatic cancer risk: a metaanalysis based on 2,049 cases and 2,861 controls. Asian Pac J Cancer Prev. 2014; 15(11): 4449–54. doi: 10.7314/apjcp.2014.15.11.4449.Wang Y., Zhang F.C., Wang Y.J. Helicobacter pylori and pancreatic cancer risk: a metaanalysis based on 2,049 cases and 2,861 controls. Asian Pac J Cancer Prev. 2014; 15(11): 4449–54. doi: 10.7314/apjcp.2014.15.11.4449.Cherif S., Bouriat K., Rais H., Elantri S., Amine A. Helicobacter pylori and Biliary Tract Cancers: A Meta-Analysis. Canad J Infec Dis Med Microbiol. 2020 (45): 1–7. doi: 10.1155/2020/9287157.Cherif S., Bouriat K., Rais H., Elantri S., Amine A. Helicobacter pylori and Biliary Tract Cancers: A Meta-Analysis. Canad J Infec Dis Med Microbiol. 2020 (45): 1–7. doi: 10.1155/2020/9287157.Zhong X., Zheng H., Zhao S., Wang Z., Su Y., Zhong K., Wang M., Shi Y. Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy. Front Immunol. 2024; 15: 1469096. doi: 10.3389/fimmu.2024.1469096.Zhong X., Zheng H., Zhao S., Wang Z., Su Y., Zhong K., Wang M., Shi Y. Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy. Front Immunol. 2024; 15: 1469096. doi: 10.3389/fimmu.2024.1469096.Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.Magahis P.T., Maron S.B., Cowzer D., King S., Schattner M., Janjigian Y., Faleck D., Laszkowska M. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2023; 11(10): e007699. doi: 10.1136/jitc-2023-007699.Che H., Xiong Q., Ma J., Chen S., Wu H., Xu H., Hou B.. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022; 22(1): 904. doi: 10.1186/s12885-022-10004-9.Che H., Xiong Q., Ma J., Chen S., Wu H., Xu H., Hou B.. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer. 2022; 22(1): 904. doi: 10.1186/s12885-022-10004-9.Zhang M.J., Chen D.S., Li S., Chen L, Qi Y.X., Zhang C.J.. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer. Invest New Drugs. 2021; 39(5): 1436–38. doi: 10.1007/s10637-021-01122-5.Zhang M.J., Chen D.S., Li S., Chen L, Qi Y.X., Zhang C.J.. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer. Invest New Drugs. 2021; 39(5): 1436–38. doi: 10.1007/s10637-021-01122-5.Shitara K., van Cutsem E., Bang Y.J., Fuchs C., Wyrwicz L., Lee K.W., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Mansoor W., Braghiroli M.I., Karaseva N., Caglevic C., Villanueva L., Goekkurt E., Satake H., Enzinger P., Alsina M., Benson A., Chao J., Ko A.H., Wainberg Z.A., Kher U., Shah S., Kang S.P., Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10): 1571–80. doi: 10.1001/jamaoncol.2020.3370.Shitara K., van Cutsem E., Bang Y.J., Fuchs C., Wyrwicz L., Lee K.W., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Mansoor W., Braghiroli M.I., Karaseva N., Caglevic C., Villanueva L., Goekkurt E., Satake H., Enzinger P., Alsina M., Benson A., Chao J., Ko A.H., Wainberg Z.A., Kher U., Shah S., Kang S.P., Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10): 1571–80. doi: 10.1001/jamaoncol.2020.3370.Lee K.W., van Cutsem E., Bang Y.J., Fuchs C.S., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Chao J., Wainberg Z.A., Cao Z.A., Aurora-Garg D., Kobie J., Cristescu R., Bhagia P., Shah S., Tabernero J., Shitara K., Wyrwicz L. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clin Cancer Res. 2022; 28(16): 3489–98. doi: 10.1158/1078-0432.CCR-22-0121.Lee K.W., van Cutsem E., Bang Y.J., Fuchs C.S., Kudaba I., Garrido M., Chung H.C., Lee J., Castro H.R., Chao J., Wainberg Z.A., Cao Z.A., Aurora-Garg D., Kobie J., Cristescu R., Bhagia P., Shah S., Tabernero J., Shitara K., Wyrwicz L. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clin Cancer Res. 2022; 28(16): 3489–98. doi: 10.1158/1078-0432.CCR-22-0121.Zhu Y., Zhu F., Ba H., Chen J., Bian X. Helicobacter pylori infection and pd-L1 expression in gastric cancer: A meta-analysis. Eur J Clin Invest. 2023; 53(2): e13880. doi: 10.1111/eci.13880.Zhu Y., Zhu F., Ba H., Chen J., Bian X. Helicobacter pylori infection and pd-L1 expression in gastric cancer: A meta-analysis. Eur J Clin Invest. 2023; 53(2): e13880. doi: 10.1111/eci.13880.Jia K., Chen Y., Xie Y., Wang X., Hu Y., Sun Y., Cao Y., Zhang L., Wang Y., Wang Z., Lu Z., Li J., Zhang X., Shen L. Helicobacter pylori and immunotherapy for gastrointestinal cancer. Innovation (Camb). 2024; 5(2): 100561. doi: 10.1016/j.xinn.2023.100561.Jia K., Chen Y., Xie Y., Wang X., Hu Y., Sun Y., Cao Y., Zhang L., Wang Y., Wang Z., Lu Z., Li J., Zhang X., Shen L. Helicobacter pylori and immunotherapy for gastrointestinal cancer. Innovation (Camb). 2024; 5(2): 100561. doi: 10.1016/j.xinn.2023.100561.Oster P., Vaillant L., Riva E., McMillan B., Begka C., Truntzer C., Richard C., Leblond M.M., Messaoudene M., Machremi E., Limagne E., Ghiringhelli F., Routy B., Verdeil G., Velin D. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022; 71(3): 457–66. doi: 10.1136/gutjnl-2020-323392.Oster P., Vaillant L., Riva E., McMillan B., Begka C., Truntzer C., Richard C., Leblond M.M., Messaoudene M., Machremi E., Limagne E., Ghiringhelli F., Routy B., Verdeil G., Velin D. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut. 2022; 71(3): 457–66. doi: 10.1136/gutjnl-2020-323392.Tonneau M., Nolin-Lapalme A., Kazandjian S., Auclin E., Panasci J., Benlaifaoui M., Ponce M., Al-Saleh A., Belkaid W., Naimi S., Mihalcioiu C., Watson I., Bouin M., Miller W., Hudson M., Wong M.K., Pezo R.C., Turcotte S., Bélanger K., Jamal R., Oster P., Velin D., Richard C., Messaoudene M., Elkrief A., Routy B. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncoimmunology. 2022; 11(1): 2096535. doi: 10.1080/2162402X.2022.2096535.Tonneau M., Nolin-Lapalme A., Kazandjian S., Auclin E., Panasci J., Benlaifaoui M., Ponce M., Al-Saleh A., Belkaid W., Naimi S., Mihalcioiu C., Watson I., Bouin M., Miller W., Hudson M., Wong M.K., Pezo R.C., Turcotte S., Bélanger K., Jamal R., Oster P., Velin D., Richard C., Messaoudene M., Elkrief A., Routy B. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. Oncoimmunology. 2022; 11(1): 2096535. doi: 10.1080/2162402X.2022.2096535.

The authors declare that there are no conflicts of interest present.